Howard Horn sold $228k of RARE
Chief Financial Officer at Ultragenyx Pharmaceutical Inc.. 10,044 shares at an average of $22.65, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +22RoleCFO
- +13Trade size$228k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-089107, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2026 | AGrant or award Common Stock10b5-1 | +6,143 | $0.00 | $0 | 95,078 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -5,290 | $22.80 | $121k | 89,788 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -3,119 | $22.54 | $70k | 86,669 | Mar 3, 2026 |
| Mar 3, 2026 | SOpen-market sale Common Stock10b5-1 | -1,635 | $22.40 | $37k | 85,034 | Mar 3, 2026 |
Related signals
Other insiders at Ultragenyx Pharmaceutical Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $17k 1,283 shares | -2% | |
| 15Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $2,252 161 shares | -0% | |
| 47Moderate | Ultragenyx Pharmaceutical Inc. | Karah Herdman Parschauer EVP and Chief Legal Officer | $208k 9,526 shares | -12% | |
| 41Moderate | Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $160k 7,029 shares | -8% | |
| 48Moderate | Ultragenyx Pharmaceutical Inc. | Erik Harris EVP & Chief Commercial Officer | $240k 10,539 shares | -11% | |
| 36Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $37k 1,632 shares | -3% | |
| 65Notable | Ultragenyx Pharmaceutical Inc. | Emil D Kakkis President & CEO | $1.2M 54,404 shares | -8% | |
| 42Moderate | Ultragenyx Pharmaceutical Inc. | Karah Herdman Parschauer EVP and Chief Legal Officer | $185k 8,135 shares | -10% | |
| 43Moderate | Ultragenyx Pharmaceutical Inc. | John Richard Pinion See Remarks | $229k 10,029 shares | -8% | |
| 10Weak | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $72k 3,061 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.